You are here: Home » Current Affairs » Coronavirus » News
Business Standard

India Coronavirus Dispatch: A look inside Serum's manufacturing facility

Falling weekly death toll, false claims about Covid-19 vaccines, how long vaccine-derived antibody protection lasts-news relevant to India's fight against Covid-19

Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Bharath Manjesh  |  New Delhi 

serum institute, coronavirus, covid, vaccine, pharma
Vaccines made by SII are accredited by the World Health Organization

A look inside Serum Institute of India's manufacturing facility

Pune-based Serum Insititute of India (SII), which manufactures Covishield, is the world's largest vaccine maker by volume. Founded by Cyrus Poonawalla in 1966, the firm has sold over 1.5 billion doses of vaccines including for Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines made by SII are accredited by the World Health Organization. They are being used in around 170 countries around the world in their national immunisation programs. A report in The Hindu provides a look inside the vaccine giant's manufacturing facility. See here

Weekly death toll less than 1,000 for the first time since May last year

For the first time since the first week of May in 2020, the country's weekly death toll from Covid-19 dropped below 1,000. The toll of fatalities in January this year was less than half of that in December and the lowest in eight months, according to a report in The Times of India.

The tally of fresh infections of the novel is also on a downward trajectory. The count in January fell below 500,000 to 4,71,282—the lowest monthly tally since June last year. Last week, the country had reported less than 100,000 infections for the first time since the June 15-21 week. Weekly infection tally is now less than 14% of the number seen at the height of the pandemic, the report said. Read more here

False claims about Covid-19 vaccines

Various false claims about Covid-19 vaccines are doing the rounds on social media. This report in the BBC brings you some widely-shared ones.

A claim that did the rounds on social media was the vaccine will lead to impotency. There is no evidence to suggest this and India's top drug regulator called the claim "absolute rubbish". Another claim says that the vaccine is free in India, while in both the US and in England you will pay. This is not true. The US government has said that Covid vaccines will be free, and the charge for administering the jab will be covered either through insurance or by a special Covid relief fund.

In England as well, which is part of the UK's National Health Service, where there are no charges for vaccines. Conspiracy theories have also falsely claimed that the vaccines contain microchips. Read more here

How lack of technology became a hurdle to justice after pandemic hit

In April last year, the Supreme Court directed that court proceedings be held through video-conferencing as a precaution against Covid-19. But, the country's justice systems were not fully equipped to tackle the emergency, according to a report in IndiaSpend. Only 6 out of 10 jails in the country had video conferencing facilities right before the pandemic struck. Less than half of all states and Union Territories had the facilities in 90% of their jails, the article said, citing a report from Tata Trusts. Read more here

How long does vaccine-derived antibody protection last?

It is not clear if protection from antibodies can last more than six months, according to a report in The Hindu. The promoters of Bharat Biotech and scientists at the ICMR say the strength of a vaccine depends on it being a "whole-inactivated virus". That means a larger surface area of the virus is visible to the body's immune system and in turn a wider range of antibodies are produced. But, antibodies from all vaccines so far are largely aimed at the spike protein. Therefore, more does not necessarily mean better. Read more here

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, February 01 2021. 14:53 IST